Takeda/Mersana Deal Adds To ADC Pipeline
This article was originally published in PharmAsia News
Mersana Therapeutics is getting a vote of confidence from long-time partner Takeda as the two companies expand their collaboration in antibody-drug conjugates and plan to move a molecule into the clinic.
You may also be interested in...
A patient death in a Phase I dose-escalation study of XMT-1522 in patients with HER2-expressing tumors rattled investors, but CEO Protopapas said it is not clear what the cause of death was in the very sick patient and that Mersana is working closely with the FDA.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.